RT Journal Article
SR Electronic
T1 Nowcasting and Forecasting the Spread of COVID-19 in Iran
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.22.20076281
DO 10.1101/2020.04.22.20076281
A1 Masjedi, Hamidreza
A1 Rabajante, Jomar F.
A1 Bahranizadd, Fatemeh
A1 Zare, Mohammad Hosein
YR 2020
UL http://medrxiv.org/content/early/2020/04/27/2020.04.22.20076281.abstract
AB Introduction As of early December 2019, COVID-19, a disease induced by SARS-COV-2, has started spreading, originated in Wuhan, China, and now on, have infected more than 2 million individuals throughout the world.Purpose This study aimed to nowcast the COVID-19 outbreak throughout Iran and to forecast the trends of the disease spreading in the upcoming month.Methods The cumulative incidence and fatality data were extracted from official reports of the National Ministry of Health and Medical Educations of Iran. To formulate the outbreak dynamics, six phenomenological models, as well as a modified mechanistic Susciptible-Exposed-Infectious-Recovered (SEIR) model, were implemented. The models were calibrated with the integrated data, and trends of the epidemic in Iran was then forecasted for the next month.Results The final outbreak size calculated by the best fitted phenomenological models was estimated to be in the range of 68,486 to 118,923 cases; however, the calibrated SEIR model estimated that the outbreak would rage again, starting from April 26. Moreover, projected by the mechanistic model, approximately half of the infections have undergone undetected.Conclusion Although the advanced phenomenological models perfectly fitted the data, they are incapable of applying behavioral aspects of the outbreak and hence, are not reliable enough for authorities’ decision adoptions. In contrast, the mechanistic SEIR model alarms that the COVID-19 outbreak in Iran may peak for the second time, consequent to lifting the control measures. This implies that the government may implement a more granular decision making to control the outbreak.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll models are in the supplementary material. Codes can be requested from the authors.